(1 - 25 von 26
)
Online-Umfrage: Darstellung von T-Zell …
www.aerzteblatt.de
Initiiert wurde das Projekt MIATA (Minimal Information About T cell Assays; www.miataproject.org) von einer Kerngruppe internationaler Experten, der auch Dr. Cedrik Britten von der III ...
Immatics weitet klinisches Studienprogramm für …
www.pressebox.de
· Cedrik Britten, MD, Chief Medical Officer von Immatics, kommentierte: „Im Rahmen unserer Strategie, unser Netzwerk an Studienzentren international zu erweitern, eröffnen wir aktuell neue ...
Community-wide Consensus Process Generates a Framework for Reporting...
www.finanznachrichten.de
"This was one of the most intense vetting processes conducted in the field of immunology," states lead author Cedrik Britten from Translational ...
RSS-Newsdeatails - Universitätsmedizin Mainz
www.unimedizin-mainz.de
Laut Dr. Cedrik Britten, Direktor Translationale Medizin von CIMT, unterscheidet sich das CIMT- Jahrestreffen gerade durch diese Aktivitäten von den üblichen Krebskongressen. „Das Cancer Immunotherapy Guiding Program ...
Immatics Announces Second Quarter Financial Results and Business...
www.wallstreet-online.de
· On June 1, Cedrik Britten, MD, joined Immatics as Chief Medical Officer (CMO). Dr. Britten previously served as Vice President and Head of Oncology Cell Therapy Research Unit at GlaxoSmithKline ...
Immatics mit erfolgreichem Börseneinstieg
www.tagblatt.de
· Juni wurde Dr. Cedrik Britten zum Chief Medical Officer (CMO) benannt. Er war zuvor Vizepräsident und „Head of Oncology Cell Therapy Research Unit“ beim britischen Pharmaunternehmen ...
Immatics Presents Data Update on Dose Escalation from ...
www.wallstreet-online.de
· Cedrik Britten, M.D., Chief Medical Officer at Immatics added: “The clinical data emerging from this early phase of our ACTengine trials provides a first evidence of anti-tumor activity at dose...
Close Biotechgate Biotechgate | | Twitter LinkedIn Google+ ...
www.maltesebiotech.com
"This was one of the most intense vetting processes conducted in the field of immunology," states lead author Cedrik Britten from Translational ...
Adoptive Cell Transfer - Global Engage
www.global-engage.com
CEDRIK BRITTEN, Head of Oncology Cell Therapy Research Unit (OCT RU), GSK • Selection of antigen(s) for CAR/TCR T cells › a...
Newsdetail : Druckansicht
www.unimedizin-mainz.de
Laut Dr. Cedrik Britten, Direktor Translationale Medizin von CIMT, unterscheidet sich das CIMT- Jahrestreffen gerade durch diese Aktivitäten von den üblichen ...
Immatics veröffentlicht Ergebnisse des zweiten Quartals sowie...
www.boerse.de
· Juni wurde Dr. Cedrik Britten zum Chief Medical Officer (CMO) von Immatics benannt. Zuvor war Dr. Britten als Vice President und Head of Oncology Cell Therapy Research Unit bei GlaxoSmithKline plc ...
Immatics Advancing T-Cell Receptor Therapies for Solid ...
www.precisiononcologynews.com
— "Cell therapy is the fastest growing sub-subspecialty within immuno-oncology," said Cedrik Britten, who joined Immatics as chief medical ... › ...
CAR-TCR Summit: Industry and patients clash on cell therapy cost |...
www.evaluate.com
Last week’s approval of Novartis’s Kymriah sent shockwaves through biopharma with the revelation that the starting cost of this CAR-T therapy would be $475,
Launch of the Immuno-Oncology Policy Action Framework - ecancerecancer.org › news › launch-of-the-immuno-o...
ecancer.org
Dr Cedrik Britten from the Cancer ImmunoTherapy Association (CIMT) echoed the position of Dr Maio on patients' literacy, and presented the work of the ...
| NDAQ:IMTX | Press Release | Immatics N.V.
stockhouse.com
— Expanded leadership team with appointment of Cedrik Britten as Chief Medical Officer and new appointments made to Immatics' board of ... ›
Gemischtes vom Tage: Immatics, Evotec, Roche, HBM
transkript.de
— ... im Vergleich zu autologen Zelltherapien von der Stange geliefert werden kann", sagte Cedrik Britten, Chief Medical Officer bei Immatics. › news › gemischtes-vom-tage-imm...
Immatics ACTengine IMA200 Interim Update, November 2021
www.marketscreener.com
— ACTengine® IMA200 TCR-T Programs Interim Phase 1a Update. Cedrik Britten, Chief Medical Officer. Harpreet Singh, Chief Executive Officer. › ...
Immatics Announces Second Quarter Financial Results and ...apnews.com › ...
apnews.com
· Expanded leadership team with appointment of Cedrik Britten as Chief Medical Officer and new appointments made to Immatics' board of ...
Immatics N : ACTengine Dose Escalation Data Updatewww.marketscreener.com › ... › News
www.marketscreener.com
· Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer March 17, © Immatics. Not for further reproduction or ...
Immatics veröffentlicht Ergebnisse des zweiten Quartals
www.globenewswire.com
· Erweiterung des Management-Teams um Cedrik Britten als Chief Medical Officer sowie Berufung weiterer neuer Mitglieder in den Aufsichtsrat ...
Immudex Takes On International Proficiency Panels
www.newswise.com
· Cedrik Britten of CIMT adds: “The CIMT Immunoguiding Program (CIP) members are excited to see that external validation for two commonly used ...
Press Release : Immatics Presents Data Update on Dose Escalationwww.marketscreener.com › ... › News
www.marketscreener.com
· Cedrik Britten, M.D., Chief Medical Officer at Immatics added: "The clinical data emerging from this early phase of our ACTengine(R) trials ...
sortiert nach Relevanz / Datum